Wugen

Biotechnology company specializing in clinical-stage immuno-oncology cell therapies. It focuses on developing off-the-shelf NK (Natural Killer) and CAR-T (Chimeric Antigen Receptor T-cell) cell therapies for treating solid tumors and hematologic malignancies, differentiating itself by using cells from healthy donors. The primary beneficiaries of Wugen's therapies are patients suffering from various types of cancer.